STA
PTCT icon

Summit Trail Advisors’s PTC Therapeutics PTCT Stock Holding History

Summit Trail Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-550
Closed -$19K – 410
2018
Q2 		$19K Buy
+550
New +$17.2K 0.01% 394
2018
Q1 		– Sell
-630
Closed -$13K – 1355
2017
Q4 		$13K Buy
+630
New +$10.7K ﹤0.01% 1157

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Summit Trail Advisors's PTCT Position: Q3 2018 in Review

Summit Trail Advisors sold out of PTC Therapeutics (PTCT) in Q3 2018, closing a stake of 550 shares — an estimated $19K sold.

Summit Trail Advisors first reported a position in PTCT in Q4 2017 and held it in 2 quarters. The position peaked at $19K in Q2 2018. 180 funds tracked by Wall St. Rank hold PTCT as of Q3 2018.

  • Summit Trail Advisors reported no remaining PTC Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 550 PTC Therapeutics shares in Q3 2018, an estimated $19K.
  • Summit Trail Advisors first reported a position in PTC Therapeutics in Q4 2017 and held it in 2 quarters.
  • Summit Trail Advisors's PTC Therapeutics position peaked at $19K in Q2 2018.
  • 180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2018.

Based on Summit Trail Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.